

## Media | Hologic

### Hologic's Affirm™ Prone Biopsy System Featured at Premier Inc. Annual Innovation Celebration

--New System Recognized for its Potential to Improve Patient Care--

MARLBOROUGH, Mass., June 22, 2016 -- Hologic, Inc. (Nasdaq: HOLX) announced today that the Company's Affirm™ prone biopsy system was one of more than a dozen products showcased in front of thousands of healthcare providers at Premier Inc.'s eighth annual Innovation Celebration in National Harbor, Maryland. The celebration is part of Premier's Breakthroughs Conference and Exhibition, which recognizes advances in healthcare from industry suppliers committed to innovation and improving patient outcomes. This is the fourth time a Hologic product has been featured at Premier Inc.'s annual event.

The Affirm™ prone biopsy system, the first dedicated stereotactic prone biopsy system to offer 2D and 3D™ imaging-guided breast biopsies, is an important step forward in biopsy technology. The system allows doctors to better target lesions found during 3D MAMMOGRAPHY™ exams, as well as other screening modalities. The new system is CE marked, FDA cleared, and commercially available in the U.S. and Europe.

"Hologic has been focused on innovating our prone biopsy system, which we know is preferred by many physicians for certain patients," said Pete Valenti, Hologic's Division President, Breast and Skeletal Health Solutions. "Now, doctors can perform prone biopsies while capitalizing on today's advances in breast imaging technology. We are honored that Premier recognized the Affirm™ prone system; it's certainly one of the most significant advancements since we introduced our first system more than 20 years ago."

Using Hologic's cutting-edge targeting and guidance technology, the Affirm™ prone biopsy system features superior image quality<sup>1</sup>, a streamlined workflow with increased automation designed to make using the system fast and easy, and 360-degree access to the breast with both standard and lateral needle approaches. The system is designed to increase patient satisfaction through faster procedure times<sup>1</sup> and comfortable prone positioning that eliminates a direct view of the biopsy needle.

For more information on the Affirm™ prone biopsy system, please visit [www.AffirmProneBiopsy.com](http://www.AffirmProneBiopsy.com).

#### **About Hologic, Inc.:**

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products. The Company core business units focus on diagnostics, breast health, GYN surgical, and skeletal health. With a unified suite of technologies and a robust research and development program, Hologic is dedicated to The Science of Sure. For more information, visit <http://www.hologic.com/>.

Genius™ 3D MAMMOGRAPHY™ exams are FDA-approved and only available on the Hologic Selenia® Dimensions® system.

Hologic, 3D, 3D Mammography, Affirm, Dimensions, Genius, MultiCare, and Selenia are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

#### **About Premier, Inc.:**

Premier, Inc. is a leading healthcare improvement company, uniting an alliance of approximately 3,000

U.S. hospitals and 110,000 other providers to transform healthcare. A Malcolm Baldrige National Quality Award recipient, Premier Inc. plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide.

Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. For more information visit [www.premierinc.com](http://www.premierinc.com).

**Forward-looking Statement Disclaimer:**

This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic mammography and breast biopsy systems. There can be no assurance the systems will achieve the benefits described here, or that such benefits will be replicated in any particular manner with respect to an individual patient. The actual effect of the use of the systems can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. In addition, there can be no assurance that the systems will achieve any expected level of sales or market share. Hologic expressly disclaims any obligation to release publicly any updates to the data or statements presented here to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based.

**Contacts:**

Media Contact:

Jane Mazur

508.263.8764 (direct)

585.355.5978 (mobile)

[jane.mazur@hologic.com](mailto:jane.mazur@hologic.com)

Investor Contact:

Michael Watts

858.410.8588

[michael.watts@hologic.com](mailto:michael.watts@hologic.com)

1. Compared to the Hologic MultiCare® Platinum prone biopsy system.